Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled study. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s114. https://doi.org/10.25251/skin.7.supp.114